411 related articles for article (PubMed ID: 32062805)
1. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
[TBL] [Abstract][Full Text] [Related]
2. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
3. Is Repeat Transurethral Resection Always Needed in High-Grade T1 Bladder Cancer?
Calò B; Chirico M; Fortunato F; Sanguedolce F; Carvalho-Dias E; Autorino R; Carrieri G; Cormio L
Front Oncol; 2019; 9():465. PubMed ID: 31214506
[TBL] [Abstract][Full Text] [Related]
4. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.
Gontero P; Sylvester R; Pisano F; Joniau S; Oderda M; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Colombo R; Briganti A; Babjuk M; Soukup V; Malmström PU; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Vakarakis J; Bartoletti R; Dalbagni G; Shariat SF; Xylinas E; Karnes RJ; Palou J
BJU Int; 2016 Jul; 118(1):44-52. PubMed ID: 26469362
[TBL] [Abstract][Full Text] [Related]
5. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
Ferro M; Vartolomei MD; Cantiello F; Lucarelli G; Di Stasi SM; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdonà S; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Verze P; Battaglia M; Serretta V; Russo GI; Morgia G; Musi G; de Cobelli O; Mirone V; Shariat SF
Urol Int; 2018; 101(1):7-15. PubMed ID: 29975950
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
7. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
[TBL] [Abstract][Full Text] [Related]
8. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
[TBL] [Abstract][Full Text] [Related]
9. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.
Shahin O; Thalmann GN; Rentsch C; Mazzucchelli L; Studer UE
J Urol; 2003 Jan; 169(1):96-100; discussion 100. PubMed ID: 12478112
[TBL] [Abstract][Full Text] [Related]
11. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
12. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
13. Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes.
Krajewski W; Moschini M; Chorbińska J; Nowak Ł; Poletajew S; Tukiendorf A; Afferi L; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Cianflone F; Mari A; Di Trapani E; Hendricksen K; Alvarez-Maestro M; Rodríguez-Serrano A; Simone G; Zamboni S; Simeone C; Marconi MC; Mastroianni R; Ploussard G; Laukhtina E; Tully K; Kołodziej A; Krajewska J; Piszczek R; Xylinas E; Zdrojowy R;
World J Urol; 2021 Jul; 39(7):2545-2552. PubMed ID: 33230571
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
[TBL] [Abstract][Full Text] [Related]
15. Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.
Baba M; Kageyama S; Yoshida T; Fujiwara R; Kim CJ; Takimoto K; Nagasawa M; Soga H; Nagatani Y; Nishikawa Z; Kawauchi A
Int J Clin Oncol; 2018 Oct; 23(5):951-956. PubMed ID: 29761307
[TBL] [Abstract][Full Text] [Related]
16. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis.
Del Giudice F; Busetto GM; Gross MS; Maggi M; Sciarra A; Salciccia S; Ferro M; Sperduti I; Flammia S; Canale V; Chung BI; Conti SL; Eisenberg ML; Skinner EC; De Berardinis E
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3073-3080. PubMed ID: 33675400
[TBL] [Abstract][Full Text] [Related]
18. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
19. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
Skinner EC; Goldman B; Sakr WA; Petrylak DP; Lenz HJ; Lee CT; Wilson SS; Benson M; Lerner SP; Tangen CM; Thompson IM
J Urol; 2013 Oct; 190(4):1200-4. PubMed ID: 23597452
[TBL] [Abstract][Full Text] [Related]
20. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]